Q-Line BiotechNSE:QLINE -5.15%12 Days Payable is 115.52 as of Mar. 2025, which is 17% below its 10-year median of 138.75. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 70.19% on this metric.
The historical rank and industry rank for Q-Line Biotech's Days Payable or its related term are showing as below:
NSE:QLINE'
s Days Payable Range Over the Past 10 Years
Min: 115.52 Med: 138.75 Max: 149.94
Current: 115.52
During the past 3 years, Q-Line Biotech's highest Days Payable was 149.94. The lowest was 115.52. And the median was 138.75.
NSE:QLINE's Days Payable is ranked better than 70.19% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs NSE:QLINE: 115.52
Q-Line Biotech's Days Payable
declined
from Mar. 2023 (138.75) to Mar. 2025 (115.52).
It may suggest that Q-Line Biotechaccelerated paying its suppliers.
Q-Line Biotech Days Payable Related Terms
Q-Line Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Days Payable Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Days Payable
138.75
149.94
115.52
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Days Payable
138.75
149.94
115.52
NSE:QLINE vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Q-Line Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Q-Line Biotech's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Days Payable of 115.52 as of Mar. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Q-Line Biotech and its competitors. This is 17% below median its historical median of 138.75. Over the past decade, Q-Line Biotech's Days Payable has ranged from 115.52 to 149.94. According to the industry distribution chart, Q-Line Biotech ranks #237 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 29.8%.
Is Q-Line Biotech's Days Payable too high?
Q-Line Biotech's current Days Payable of 115.52 is 17% below median its 10-year median of 138.75. Over the past 10 years, this metric has ranged from a low of 115.52 to a high of 149.94. The Medical Devices & Instruments industry median Days Payable is 68.07. Q-Line Biotech's value of 115.52 is 69.7% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #237 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #237 out of 795 companies for Days Payable. This puts Q-Line Biotech in the upper half of its industry. The industry median Days Payable is 68.07. Q-Line Biotech's value of 115.52 is 69.7% above this benchmark. Historically, Q-Line Biotech's own Days Payable has ranged from 115.52 to 149.94 over the past decade. While the company's 10-year median is 138.75 vs. the industry median of 68.07, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Days Payable of 115.52 is 69.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Days Payable is 115.52, which is 17% below median its own 10-year median of 138.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Days Payable of 115.52. The current Days Payable is 115.52, which is 17% below median its 10-year median of 138.75 and 69.7% above the Medical Devices & Instruments industry median of 68.07. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Days Payable is 115.52 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 